Association of Epstein‑Barr virus infection with allogeneic hematopoietic stem cell transplantation in patients in Portugal.

The identification of patients at higher risk of developing Epstein‑Barr virus (EBV) infection in hematopoietic stem cell transplants (HSCT) is useful for the prevention of EBV‑associated diseases A prospective observational study was developed that included 40 patients (27 male and 13 females, with mean age of 32.2±1.5 years old) undergoing allogeneic‑HSCT between January and December 2015. EBV was examined in whole blood samples collected during routine procedures at day (D)+30, D +60, +90, D+120, D+150 and D+180 post‑transplant. EBV was detected, at least once during the follow‑up period in 70.0% of our patients. Results indicated that patients with unrelated donors had increased risk of developing EBV infection at D+60 and D+150 (OR=3.9, P=0.058; OR=8.0, P=0.043; respectively). Moreover, myeloablative conditioning (OR=4.3, P=0.052), anti‑thymocyte globulin use (OR=12.0, P=0.030) and graft‑vs.‑host disease (OR=6.7, P=0.032) were associated with EBV infection at D+60, D+150 and D+90, respectively. In our series, none of these patients developed post‑transplant lymphoproliferative disease. To the best of our knowledge, the present study is the first study to report EBV infection in patients undergoing aHSCT from Portugal. The study revealed that EBV infection is associated with different factors. These findings provide evidence towards the identification of high‑risk patients for EBV‑infection and associated disease.